What is cGP

cGP (Cyclic Glycine-Proline) is a key molecule produced by the body that helps support blood circulation. The blood circulation system comprises of blood vessels; arteries, veins and capillaries. In order to keep the blood circulation going in the brain, hormones such as IGF-1 play a crucial role. cGP helps balance the levels of IGF-1 activity and normalises it.

As age increases, low levels of IGF-1 obstruct the healthy functioning of the blood circulation system, leading to discomforting symptoms such as low energy, age-related cognitive decline, compromised mood, irritability, and disrupted sleep. Increasing the concentration of cGP will help normalise IGF-1 levels and provide comfort.

Look after your brain so your brain can look after you

The brain is the command centre for the nervous system that controls thoughts, memory, movement and emotions. As the brain is the most nutrient hungry organ in our body, it needs a constant supply of nutrients.

Simultaneously, it also produces waste material which cause tissue degeneration if not cleared.

Your brain is the essence of who you are so it makes sense to look after it as you age.

The Circulatory System Decoded

Our blood circulatory system is responsible for two very important functions :

1) The transport of essential nutrients and oxygen to the brain
2) Removal of toxic waste products.

It comprises of 3 types of blood vessels – arteries, veins and capillaries that work together to maintain healthy blood circulation. Normal circulation is essential for delivering medicine and the uptake of nutrients and oxygen, making it a crucial process in the pursuit of health and longevity.

cGP (cyclic-Glycine-Proline) is a molecule in our body that facilitates the process of building new blood vessels and supports the circulatory system. As we age, a natural decline in cGP levels prevents the building of new blood vessels.

In the absence of new blood vessels, old ones become worn out and eventually die leaving gaps in blood circulation, resulting in reduced blood flow. Since the brain no longer receives the nutrients it needs, then begins the occurrence of age-related symptoms of issues such as lack of mental clarity, loss of focus, forgetfulness, lack of sleep, irritability, and a poor quality of life.

As the body’s need for cGP increases with age, its ability to produce cGP decreases. Thus, implying the need for supplementation.

cGPMAX Brain Health is the world’s first 100% natural product that supplements the body’s cGP levels and contributes to optimal brain health.

Nootropics vs Longevity

A healthy brain constantly produces new blood vessels to replace the loss of capillaries (small blood vessels). The body’s ability to make new blood vessels diminishes with age [17]. As a result, the capillary nets that deliver oxygen and nutrients to brain cells are getting fewer and fewer with age. Undernourished brain cells do not work and the build-up of toxins can kill the brain cells slowly causing brain degeneration.

The function of cGP is to encourage the cells in the brain to make new blood vessels [1, 4] and taking a daily dose of our cGPMAX™ supplement allows the body to produce more blood vessels, increasing blood circulation in the brain. A study shows that older healthy people with higher levels of cGP in their blood circulation show better memory and other cognitive function [6]. Gradually increasing the level of cGP in the blood as the body ages is the key to keeping cognitive function normal whereas people with dementia show a gradual decreasing of cGP as they age [6].

Increasing cGP levels through supplementation or intervention, such as cGPMAX™ may help older people retain their memory and slow down the progress of memory decline and preventing dementia.

What is the secret of cGPMAX?

Here at cGPMAX we believe nature provides the best solution.

cGPMAX Brain Health capsules are made from NZ grown blackcurrants, which contain cGP in their food matrix. The cGP is extracted from a particular part of the blackcurrants. It undergoes a highly regulated process, designed by our science team, to convert it from food to brain food, while retaining its properties.

cGPMAX is designed to deliver a daily dose of cGP, helping maintain the cGP reserves in our body. The use of natural ingredients makes them favourable for the body, and supplements body’s cGP reserve with any excess being passed out in urine.

We hold local and international patent applications for our cGP science, and technology with regard to the manufacture and application of cGP related products.

Shop Now

What is cGP?

cGP (Cyclic Glycine-Proline) is a key molecule in your body whose job is to regulate the function of a life-supporting hormone called IGF-1 (Insulin-like Growth Factor 1).

IGF-1 is responsible for making capillaries - the smallest blood vessels in our body. They transport oxygen and nutrients to cells and remove waste from our brain and main organs.

Our IGF-1 function reduces as we age, or can occur prematurely as a result of poor lifestyle and stress.

Taking a daily dose of cGPMAX™ increases the cGP levels in your body, in turn powering the IGF-1 to produce more capillaries.

If you would like to know more about the science of cGP and IGF-1 and how it positively impacts health outcomes, we have an extensive list of scientific papers and research available. Learn More...

In other words…

Let’s use an analogy to better explain the role of cGP and IGF-1…

Imagine the blood vessels in your body are roads in a city, and the IGF-1 is responsible for road maintenance.

As the city grows over time and the roads are under constant use, the original roads will not last, they will deteriorate until the cars can no longer use them.

When we are young the roads are being constantly maintained. However, as we age our IGF -1 levels drop so IGF-1 just doesn’t do any road maintenance or doesn’t build new roads.

In addition to ageing, when a person is young and a natural disaster strikes the body, (for example caused by injury or stress), there is an increased use of the body’s roading system. This causes a greater need for road maintenance.

This is where the cGP becomes the hero. The cGP acts like a superfood and fuels the IGF-1 and the more cGP you put into your body, the faster and harder the IGF-1 works to repair body’s roading system, facilitating the delivery of oxygen and nutrients to the cells in the brain and body and enabling the removal of waste.

How cGP powers your brain

The brain is the most important organ in our body. If our brain is not functioning properly, we are unable to have conversations with those we love, read a book, cook dinner or find our way home.

Unfortunately, when our bodies are low in cGP, our brains are most affected, leaving us vulnerable to a whole range of poor health outcomes such as dementia, Parkinson’s, stroke, Alzheimer’s, hypertension and other diseases.

cGPMAX™ Brain Health

There is no known way of medically controlling the IGF-1 function in our body. Taking a cGPMAX Brain Health is the only known way to regulate the IGF-1 to keep it functioning at its optimum level for good health.

cGPMAX™ Brain Health has been scientifically researched and formulated to increase the supply of nutrients to the brain, supporting brain health and function as we age.

It is 100% naturally sourced and you cannot have too much as any excess is passed out with your urine.

Take your brain health into your own hands and start the cGPMAX™ journey with a Brain Health Start Pack.

Age Well with cGP

Our Chief Scientist Dr Jian Guan has written over 80 scientific papers about the role of cGP and how it effects people suffering from various neurodegenerative diseases.

We encourage you to have a look our scientific papers to understand how cGP impacts the effects of these diseases and can work towards easing the effects of the disease to give people a better outcome for their future.

A Selected List of cGPMAX™ Scientific Papers

2021 Singh-Mallah G, Ardalan M, Singh K, Kang D, McMahon C, Mallard C and Guan J. Administration
of cyclic glycine-proline during infancy improves adult spatial memory,
astrocyte plasticity, vascularization and GluR-1 expression in rats.
Nutritional Neuroscience. August 20212021 Kang D, Waldvogel H, Fan D, Wang A, Faull R, Curtis M, Shorten P and Guan J. The autocrine regulation in human brain of Alzheimer’s diseases. Accepted with revision in Psychoneuroendocrinology2020 Fan D, Pitcher T, Dalrymple-Alford J, MacAskill M, Anderson T and Guan J. Plasma cGP/IGF-1 molar ratio is associated with cognitive status of Parkinson disease. Alzheimer’s Dement. 2020;1–10. 2019 Li FX, Liu K, Gray C, Harris P, Reynolds C, Vickers M and Guan J. Cyclic glycine-proline normalizes systolic blood pressure in high-fat diet-induced obese male rats. Nutrition, Metabolism & Cardiovascular Diseases. 30: 339-346 2019 Li FX, Liu K, Wang A, Harris P, Vickers M and Guan J. Cyclic Glycine-Proline Administration Normalizes High-Fat Diet-Induced Synaptic Expressions in Obese Rats. Neuropeptides 76, 101935, 10.1016/j.npep.2019.05.0062019 Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J. Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients. Annals of Clinical Translational Neurology 2019;0 2018 Fan D, Alamri Y, Liu K, MacAskill M, Harris P, Brimble M, et al. Supplementation
of Blackcurrant Anthocyanins Increased Cyclic Glycine-Proline in the
Cerebrospinal Fluid of Parkinson Patients: Potential Treatment to
Improve Insulin-Like Growth Factor-1 Function.
Nutrients 2018;10:714. doi:10.3390/nu10060714. 2018 Alamri Y, The use of dietary supplements and perceived quality of life in patients with Parkinson's disease. J Clin Neuroscience 56: 137-1362018 GUAN J, SINGH-MALLAH G, LIU K, SHORTEN P, THOMPSON J, MITCHELL
E, TAYLOR R, HARRIS P, BRIMBLE M, THORSTENSEN E AND MURPHY R. The role for autocrine regulation of IGF-1 in pregnancy related obesity, a potential biomarker for weight changes. Journal of Biological Regulators and Homeostatic agents 32(3): 11-25 2017 SINGH-MALLAH G, MCMAHON CD, GUAN J and SINGH K Cyclic-glycine-proline promotes post-lactational involution in mammary glands of rats through inhibiting IGF 1 function. Journal of Cellular Physiology 232 (12) 3369-3383doi: 10.1002/jcp.25782 2016 SINGH-MALLAH G, SINGH K, MCMAHON CD, HARRIS P, BRIMBLE MA and GUAN J, Maternal-infantile
transfer following oral administration of cyclic-glycine-proline in
lactating rats and its effect on improving memory in the offspring
Endocrinology 157(8):3130-9 2017 YANG P, WALDVOGEL H, Scott E, FAULL R, DRAGUNOW M, TURNER C, AND GUAN J. Endothelial degeneration of Parkinson disease is related to alpha-synuclein aggregation. Journal of Alzheimer’s Disease & Parkinsonism 7: 370. doi: 10.4172/2161-0460.1000370 2017 YANG P, WALDVOGEL H, FAULL R, DRAGUNOW M, TURNER C, AND GUAN J. Vascular remodelling is impaired in Parkinson’s diseases, Journal of Alzheimer’s Disease & Parkinsonism 7: 313. doi: 10.4172/2161-0460.1000313 2015 Yang P, Pavlovic D, Richard Faull, Mike Dragunow Beth Synek, Clinton Turner Henry Waldvogel and Guan J, String vessel formation is increased in the brain of Parkinson disease. J of Parkinson Diseases. 5 (2015) 821–83620152015 GUAN J, HARRIS P, BRIMBLE M, LEI Y, LU J, YANG Y AND J GUNN A, The
role for IGF-1 derived small neuropeptides as a therapeutic target for
neurological disorders. Expert Opinion on Therapeutic Targets.
Invited review 2015 Feb 5:1-9 2015 PHILLIPS GMA, SHORTEN PR, WAKE GC AND GUAN J, Dynamical modelling of the effect of insulin-like growth factor -1 on human cell growth. Mathematical Bioscience Journal 2015 Jan; 259:43-54. 2014 GUAN J, GLUCKMAN PD, YANG PZ, KRISSANSEN G, SUN K, ZHOU Y, WEN
REN AND LIU DX, Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1 Scientific Report, 4, 43882014 MATHAI S, GUNN AJ, BRIMBLE MA, HARRIS PW AND GUAN J. Neuroprotection with Glycin-2methyl-Proline-Glutamate (G-2mPE) after hypoxic-ischemic brain injury in adult rats. Journal of Experimental Stroke Translational Medicine 6: 1-1120132013 GUAN J, MATAI S, LIANG HP AND GUNN JA Insulin-like growth factor-1 and its derivatives: Potential pharmaceutical application for treating neurological conditions. Recent Patents on CNS drug discovery 2013 8(2) 142-168 2013 Guan J, Pavlovic D, Darkie N, Waldvigel H, Green C and Nicholson L. Vascular degeneration of Parkinson Disease. Brain Pathology 23(2) 154-164 (impact factor 4.7 doi: 10.1111/j.1750-3639.2012628)2012 MATHAI S, GUNN AJ, BACKHAUS A AND GUAN J Window of opportunity for neuroprotection with an antioxidant, Allene Oxide Synthase, after hypoxia-ischemia in adult male rats, Journal of Neuroscience and Therapeutics 18(11):887-94 2012 ZHANG R, KADAR T, SIRIMANNE E, MACGIBBON A AND GUAN J Age-related memory decline in rats is associated with vascular and microglial degeneration, Behavioural Brain Research 1;235(2):210-7 2010 GUAN J, ZHANG R, L DALE GANDAR AND VICKERS M. NNZ-2591, A novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behavioural Brain Research 210, 221-228. 2009 GUAN J AND GLUCKMAN P. Endogenous small neuropeptides
and their analogues: a novel strategy for the development of
pharmaceuticals for neurological conditions
, invited review by British Journal of Pharmacology 157, 881-8912009 SHAPIRA S, MATHAI S, ZHANG R AND GUAN J Delayed
peripheral administration of the N-terminal tripeptide of IGF-1 (GPE)
reduces brain damage following microsphere induced embolic damage in
young adult and aged rats.
Neuroscience Letter 454 (1) 53-572009 KRISHNAMURTHI, R V M., KIM A H., MATHAI S. RONG ZHANG AND GUAN J. Delayed treatment with a novel diketopiperazine improves motor function after 6-OHDA lesion in rats. British Journal of Pharmacology 156, 662-672.2008 JACOBSON L, ZHANG R, ELLIFFE D, CHEN C, MATHAI S, MCCARTHY D, WALDVOGE H AND GUAN J. Co-relation of cellular/vascular changes and spatial memory during aging in rats Experimental Gerontology 43, 928-9382007 GUAN J, MATHAI S, HARRIS P, BRIMBLE M, WEN JY ZHANG R and GLUCKMAN P Peripheral
administration of a novel diketopiperazine, NNZ 2591 prevents brain
injury and improves somatosensory-motor function following
hypoxia-ischemia in adult rats.
Neuropharmacolocy 53: 749-762 2007 SVEDIN P, GUAN J*(co-responding author), MATHAI S, ZHANG R, WANG XY, HAGBERG H AND MALLARD C Delayed
peripheral administration of a GPE analogue induces astrogliosis and
angiogenesis and reduces inflammation and brain injury following
hypoxia-ischemia in the neonatal rat
. Developmental neuroscience 29: 393-402 2005 BAKER A M, BATCHELOR D C, THOMAS G B, CLARK R G, RAFIEE M, LIN H AND GUAN J Central
penetration and the stability of N-terminal tripeptide of insulin-like
growth factor-I, glycine-proline-glutamate in adult rat.
Neuropeptides 39(2) 81-872004 GUAN J, THOMAS G B, LIN H, MATAI S, BACHELOR D C, GEORGE S, FERNANDEZ J AND GLUCKMAN PD Neuroprotective
effects of the N-terminal tripeptide of insulin-like growth factor –1,
glycine-proline-glutamate (GPE) following intravenous infusion in
hypoxic-ischemic adult rats.
Neuropharmacology Vol 47 (6): 892-9032004 KRISHNAMURTHI R, STOTT S, MAINGAY M, FAULL RLM, MCCARTHY D, GLUCKMAN PD AND GUAN J. N-terminal tripeptide of insulin-like growth factor –1 (GPE) improves functional deficits after 6-OHDA lesion in rats. NeuroReport 15(10); 1601-1604 2003 GUAN J, BENNET L PD GLUCKMAN AND GUNN AJ, Insulin-like growth factor-1 and the ischemic brain. Progress in Neurology 70 (6), 443-462 2000 GUAN J., KRISHNAMURTHI, R., WALDVOGEL, H.J., FAULL, R.L.M., CLARK, R. AND GLUCKMAN, P. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Research 859 (2) 286-292,1999, GUAN J, WALDVOGEL H, FAULL R, GLUCKMAN P AND WILLIAMS C The
effects of the N-terminal tripeptide of insulin-like growth factor-1,
glycine-proline-glutamate in different regions following
hypoxic-ischemic brain injury in adult rats.
Neuroscience 89: 649-659